Overview

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Status:
Recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

This study is an open-label, single arm phase II study which will examine the efficacy and toxicity of the combination therapy of GO, mitoxantrone and etoposide in patients who did not respond to first line induction therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Konstantinos Lontos
Michael Boyiadzis

Collaborator:

Pfizer

Treatments:

Etoposide
Etoposide phosphate
Gemtuzumab
Mitoxantrone